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Background: In order to design studies assessing the optimal use of bone-targeted agents (BTAs) patient
input is clearly desirable.
Methods: Patients who were receiving a BTA for metastatic prostate or breast cancer were surveyed at
two Canadian cancer centres. Statistical analysis of respondent data was performed to establish relevant
proportions of patient responses.
Results: Responses were received from 141 patients, 76 (53.9%) with prostate cancer and 65 (46.1%) with
breast cancer. Duration of BTA use was o3 months (15.9%) to 424 months (35.2%). Patients were
uncertain how long they would remain on a BTA. While most felt their BTA was given to reduce the
chance of bone fractures (77%), 52% thought it would slow tumour growth. Prostate patients were more
likely to receive denosumab and breast cancer patients, pamidronate. There was more variability in the
dosing interval for breast cancer patients. Given a choice, most patients (49–57%) would prefer injection
therapy to oral therapy (21–23%). Most patients (58–64%) were interested in enrolling in clinical trials of
de-escalated therapy.
Conclusion: While there were clear differences in the types of BTAs patients received, our survey showed
similarity for both prostate and breast cancer patients with respect to their perceptions of the goals of
therapy. Patients were interested in participating in trials of de-escalated therapy. However, given that
patients receive a range of agents for varying periods of time and in different locations (e.g. hospital vs.
home), the design of future trials will need to be pragmatic to reﬂect this.
& 2013 Elsevier GmbH. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Despite the widespread use of bone-targeted agents in the care
of patients with bone metastases from prostate and breast cancer,
questions regarding the optimal; choice of agent, dose, dosing
frequency, and duration of therapy remain unanswered [1–6].
Our research group is interested in designing and performing
pragmatic de-escalation trials in both breast and prostate cancer
patients. However, before undertaking this research, it is important
to survey potential patients regarding this type of study with. This is an open access article und
cer Centre, Box 912, Division
anada K1H 8L6.
).respect to their understanding of their disease and use of their
bone-targeted therapies (i.e. denosumab, zoledronate, pamidronate
or clodronate). The information obtained will facilitate appropriate
pragmatic trial designs, which will positively impact patients’
potential willingness to participate.
This report summarizes the conduct and ﬁndings of a survey
designed to collect information from Canadian patients with breast
or prostate cancer regarding their views of their current treatment
regimen. In addition, their opinions regarding the possibility of less
frequent treatment administrations and participation in potential
research studies to assess the effectiveness of this treatment option
were also sought. While we are aware of similar patient surveys
around the use of bone-targeted agents for osteoporosis [7] and
multiple myeloma [8], we are not aware of published work in
patients with metastatic bone disease from solid tumors.er the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Overview of respondent population.
Respondent characteristics Distribution of responses
Breast cancer Prostate cancer Overall
Number of respondents 65 (46.1%) 76 (53.9%) 141
Cancer spread to bones?
Yes 65 (100%) 76 (100%) 141 (100%)
No 0 0 0
Previous bone targeted agent therapy?
Yes 65 (100%) 72 (94.7%) 137 (97.2%)
No 0 (0%) 3 (3.9%) 3 (2.1%)
No response 0 1 (1.3%) 1 (0.7%)
Duration of bone targeted agent therapy?
o3 months 8 (12.3%) 16 (21.1%) 24 (17.0%)
3–12 months 21 (32.3%) 32 (22.7%) 53 (37.6%)
12–24 months 14 (21.5%) 17 (22.4%) 31 (22.0%)
424 months 22 (33.8%) 5 (6.6%) 27 (19.1%)
No response 0 (0%) 6 (7.9%) 6 (4.3%)
Expectations, bone targeted agent treatment duration?
2 years 0 (0%) 0 (0%) 0 (0%)
As long as I am well enough 5 (7.7%) 2 (2.6%) 7 (5.0%)
As long as my doctor prescribes 30 (46.2%) 31 (40.8%) 61 (43.2%)
Unknown 29 (44.6%) 34 (44.7%) 63 (44.7%)
Other 0 (0%) 1 (1.3%) 1 (0.1%)
No response 1 (1.5%) 8 (10.5%) 9 (6.4%)
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2.1. Survey development
The survey was designed to collect speciﬁc information about
the use of current bone-targeted therapy and patients’ perception
of the goals of this treatment and alternative treatment schedules.
Second, the survey gathered information regarding their perspec-
tives on the concept of de-escalated bisphosphonate therapy,
designed to help the study team develop an understanding of
how patients would value a change in their therapy. Our survey
was conceived and developed using an iterative approach by the
research team with backgrounds in oncology and epidemiology,
including expertise in survey design. The survey is provided in
a supplemental appendix.
2.2. Study population
Patients attending outpatient clinics at two Canadian cancer
centres (The Ottawa Hospital Cancer Centre in Ottawa and the
Sunnybrook Odette Cancer Centre in Toronto, Canada) who were
receiving or had recently been receiving bone-targeted therapy for
bone metastases from either prostate or breast cancer were
approached. The survey was available in both paper and online
formats (implemented via www.ﬂuidsurveys.com), whichever the
patient preferred to use, and took about 10 min to complete.
The survey was open to patients seen between August 1st and
October 31st, 2012. Local institutional research ethics board (REB)
approval for the study was granted at both participating hospitals.
However, given the REB requirement that no personal patient
identiﬁers could be collected, we were unable to collect informa-
tion on the number of patients who took the survey away from
clinic but then chose not to complete it. As a result, a response rate
cannot be calculated.
2.3. Statistical analysis
The survey consisted of close-ended multiple-choice and
hybrid questions (i.e. choose-one-and specify) which were ana-
lyzed using a descriptive summary of ﬁndings in the form of
frequencies and percentages using Microsoft Excel 2010 (Microsoft
Corporation, Seattle, Washington) and SAS software (version 9.2,
SAS, Cary, North Carolina). There were no formal hypotheses
tested using the data. This data was used to qualitatively judge
the respondents’ views of their current treatments and to deter-
mine their willingness to be treated with de-escalated bone-
targeted therapy to allow the study team to clarify the value and
feasibility of a future trial around this clinical question. Analyses
were performed to present the overall response proﬁle, as well as
responses within the breast cancer and prostate cancer subgroups.
Bar plots were generated to help present categorical data ﬁndings.3. Results
3.1. Respondent population characteristics
A total of 141 patients responded, and included totals of
65 (46.1%) and 76 (53.9%) patients diagnosed with breast
cancer and prostate cancer, respectively (Table 1). All patients
had bone metastasis. A total of 100% of breast cancer patients and
94.7% of prostate cancer patients were aware that they had
received treatment with a bone-targeted agent at some point.
Respondents had received bone-targeted agents for: o3 months
(17.0%), between 3 and 12 months (37.6%), between 12 and 24
months (22.0%), and 424 months (19.1%); 4.3% of patients did notrespond. Patients varied in the amount of time for which they
expected to remain on therapy: 44.7% did not know for how long,
43.2% indicated as long as their doctor keeps prescribing it, 5.0%
believed it to be as long as they remain well enough to attend their
centre to receive it, and 6.4% did not respond. These response
patterns were similar for breast cancer and prostate cancer
patients with a few small differences noted (Table 1).
3.2. Current treatment
Among prostate cancer patients, the most commonly adminis-
tered agent was denosumab (63.1%, as well as an additional 5.3%
who in the past had received denosumab), followed by zoledronic
acid (19.7%) (Fig. 1). Overall 44.7% of patients received their
treatment at the hospital chemotherapy unit, while 27% received
treatment via injections administered at home by a nurse or
another individual (Fig. 2). A total of 31 patients (40.8% of all
prostate cancer patients, or 45.6% of those responding to the
related question) reported being aware of potential side effects
of their treatment. According to patients’ descriptions, the poten-
tial side effects of bone targeted agents were; diarrhoea, constipa-
tion, vomiting, fatigue, ﬂu-like symptoms, osteonecrosis of the
jaw, hypocalcaemia, bone pain and water retention.
Within the breast cancer cohort, the most commonly used
agent was pamidronate (87.7%), followed by zoledronic acid (9.2%;
Fig. 1). Overall, 93.8% of patients reported receiving their treat-
ments in the chemotherapy unit at their hospital (Fig. 2). Overall,
34 patients (52.3%) were receiving their treatment every 3 months
(Fig. 3). A total of 28 patients (43.1%) reported awareness of
potential side effects, similar to those described by prostate cancer
patients.
3.3. Patient's viewpoints regarding the indication for current
bone-targeted treatment
The most commonly reported reasons were: to reduce the
chance of bone fractures due to cancer (78.0%), to slow the growth
of cancer (53.2%), to reduce the chance of spinal damage (49.0%),
to prolong survival (46.8%), and to reduce the chance of cancer
pain (46.1%) (Fig. 4). Fewer patients indicated that it was related
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to the management of hypercalcaemia (24.1%).
3.4. Patients’ viewpoints regarding potential changes in therapy
The majority of respondents with prostate cancer (78.9% overall,
or 93.5% of those that responded to the related question) and breast
cancer (75.4% overall, or 87.3% of those that responded to the
related question) would be willing to take a reduced dose of their
medication if it were associated with the same clinical beneﬁts as
their current dose. Similarly, the majority of respondents with
prostate (67.1% overall, or 79.7% of those responding to the relatedquestion) and breast cancer (69.2% overall, or 88% of those responding
to the related question) indicated they would be happy taking the
medication less often (i.e. leaving the dose unchanged but receiving it
less frequently) if the clinical beneﬁts were unchanged.
Eighteen and a half percent and 30.3% of breast and prostate
cancer respondents, respectively, indicated a lack of interest in
changing from their current 3–4 week regimen. If reducing the
dose would lead to fewer side effects, 64.6% of prostate cancer and
46.1% of breast cancer patients indicated an interest in taking
a reduced medication schedule and dose.
When asked if they would prefer a daily oral medicine or an
injection in the hospital every 1–3 months, 21.1% of prostate
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Fig. 4. Summary of why patients believe they receive bone-targeted treatment.
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preference for taking oral medication daily, while 57.9% and 49.2%
preferred an injection every 1–3 months. An additional 19.5% and
13.4% of patients did not respond. Overall, 39.2% of prostate cancer
patients and 35.4% of breast cancer patients indicated a will-
ingness to administer their own medication via an injection. When
asked if they would be willing to enter a trial randomising
between monthly and 3 monthly therapy, 64.6% of prostate
patients and 58.2% of breast cancer patients indicated a will-
ingness to participate in such a study.4. Discussion
Despite the widespread use of bone-targeted agents in the care
of patients with bone metastases from prostate and breast cancer,
a number of important and practical clinical questions remain
around optimising their use. In order to design and perform
pragmatic clinical trials in these populations, it is important to
obtain patient treatment information, perceptions and opinions
that will help guide trial design to ensure sufﬁcient participation.
This is of particular interest for studies evaluating treatment
de-escalation where it is critical to ascertain patient's willingness
to participate. To our knowledge, we are the ﬁrst team to
implement use of this type of survey in these patient populations,
although a number of de-escalation studies are either reported
[4–7] or are ongoing [8].
Our survey demonstrates that Canadian breast cancer patients
are more likely to receive pamidronate, whereas prostate cancer
patients are more likely to receive either denosumab or zoledronic
acid. These differences reﬂect not only that the drugs proven to be
efﬁcacious in these populations are different (i.e. only denosumab
and zoledronic acid improve outcomes in prostate cancer), but also
that the funding system for these agents in Ontario differs. Any
trial looking at de-escalated therapy will need to take these factors
into account. Our ﬁndings also suggest that clinical trials evaluat-
ing single agents such as zoledronic acid or denosumab [4–6] will
not lead to broad changes in clinical practice in both disease sites.
Trials will therefore need to reﬂect the diversity of treatments
offered. In addition, for prostate cancer patients, such a trial will
need to reﬂect the fact that a signiﬁcant number of patients have
switched from zoledronic acid to denosumab when funding for
denosumab became available, thus future studies may have to
allow for bisphosphonate use prior to denosumab treatment in the
inclusion criteria.
Patients in our survey population had been on bone-targeted
agents for variable periods of time, again meaning that futuretrials will need to be reﬂective of this, and be ﬂexible in the length
of time a patient has been on a prior bone-targeted agent prior to
study entry. To date, of the published trials [4,7], only one [5] did
not specify the maximum length a patient could have been on
a prior agent.
Interestingly, many patients perceived that the bone-targeted
agent was slowing the growth of their cancer. Given that these
agents have shown no effect on either overall survival or
progression-free survival in breast cancer [9–13]. [6,14] or prostate
cancer [15,16], there may be a need to better inform patients of
this fact.
Preference for injectable therapy over oral therapy [17],
contrary to our ﬁndings from a previous study [18], could reﬂect
the fact that most patients have not received an oral bone-targeted
agent for metastatic disease. However, the practical advantages of
an injectable therapy and the lack of need for extra-care (taking
the medication with water, not laying down shortly after PO
administration) in an elderly patient population should not be
ovelooked.
There are limitations to our study. Our sample was recruited
from two cancer centres in Ontario, Canada and therefore reﬂects
prescriptions practices in that Province. In addition, as the REB
requirement was to allow no patient identiﬁers on the question-
naires, we could not tell how common it was for patients to refuse
participation (i.e. in place of a denominator for response rate,
which we do not have). As a consequence, it is possible that our
responding cohort consists of better informed, more motivated
patients which may not be representative of all patients receiving
treatment with bone targeted agents. This too could be reﬂected
by the large number of breast cancer patients who are already
receiving 3-monthly bone-targeted therapy [2].5. Conclusion
In an era of personalised medicine, involvement of patients in
the design of future clinical trials is increasingly important.
Although our results suggest that patients still have misconcep-
tions around the reasons for receiving bone-targeted agents, the
similarities between prostate and breast cancer patients are
interesting as both patient populations were aware of the main
indications and toxicities of these agents. Patients are interested in
trials of de-escalated therapy. However, given that patients receive
a range of agents for varying periods of time and in different
locations (hospital vs. home) means that the design of future trials
will need to reﬂect this and be very pragmatic.
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